Mucosal Immunology and Biology Research Center, Mass General Brigham, Harvard Medical School, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy.
Gut Microbes. 2024 Jan-Dec;16(1):2392009. doi: 10.1080/19490976.2024.2392009. Epub 2024 Aug 19.
Here, we explored the vast potential of microbiome-based interventions in preventing and managing non-communicable diseases including obesity, diabetes, allergies, celiac disease, inflammatory bowel diseases, malnutrition, and cardiovascular diseases across different life stages. We discuss the intricate relationship between microbiome and non-communicable diseases, emphasizing on the "window of opportunity" for microbe-host interactions during the first years after birth. Specific biotics and also live biotherapeutics including fecal microbiota transplantation emerge as pivotal tools for precision medicine, acknowledging the "one size doesn't' fit all" aspect. Challenges in implementation underscore the need for advanced technologies, scientific transparency, and public engagement. Future perspectives advocate for understanding maternal-neonatal microbiome, exploring the maternal exposome and delving into human milk's role in the establishment and restoration of the infant microbiome and its influence over health and disease. An integrated scientific approach, employing multi-omics and accounting for inter-individual variance in microbiome composition and function appears central to unleash the full potential of early-life microbiome interventions in revolutionizing healthcare.
在这里,我们探讨了基于微生物组的干预措施在预防和管理非传染性疾病方面的巨大潜力,这些疾病包括肥胖症、糖尿病、过敏、乳糜泻、炎症性肠病、营养不良和心血管疾病,涵盖了不同的生命阶段。我们讨论了微生物组与非传染性疾病之间的复杂关系,强调了在出生后最初几年中微生物-宿主相互作用的“机会之窗”。特定的生物制剂和活体生物治疗剂,包括粪便微生物移植,作为精准医学的关键工具出现,承认了“一刀切”并不适用的情况。实施过程中的挑战突显了对先进技术、科学透明度和公众参与的需求。未来的观点主张深入了解母婴微生物组,探索母体外显组,并研究母乳在建立和恢复婴儿微生物组及其对健康和疾病的影响中的作用。采用多组学方法并考虑微生物组组成和功能的个体间差异的综合科学方法,似乎是释放生命早期微生物组干预措施在改变医疗保健方面的全部潜力的核心。
Adv Exp Med Biol. 2024
Microbiol Mol Biol Rev. 2017-11-8
Endocr Metab Immune Disord Drug Targets. 2024
FEMS Microbiol Rev. 2021-9-8
Front Cell Infect Microbiol. 2025-8-14
Int J Mol Sci. 2025-7-30
Front Cell Infect Microbiol. 2025-7-7
J Clin Invest. 2025-6-2
Gut Microbes. 2025-12
Cell Host Microbe. 2024-2-14
NPJ Biofilms Microbiomes. 2024-1-6
Nat Rev Gastroenterol Hepatol. 2024-1
JAMA Netw Open. 2023-12-1
Pediatrics. 2024-1-1